Status:
UNKNOWN
Substitution of First Phase Insulin Response in Patient With Type 2 Diabetes.
Lead Sponsor:
University Hospital, Gentofte, Copenhagen
Conditions:
Type 2 Diabetes
Eligibility:
All Genders
35-75 years
Phase:
PHASE4
Brief Summary
The purpose of the project is to shown whether a little dose of a short acting insulin analogue given 3 time daily before the meals compared with placebo could normalise the increase in blood glucose ...
Detailed Description
Patients with Type 2 diabtes has a defect in the insulinsecretion combined with an increased insulin resistance. At an intravenously glucosestimulation, patients with Type 2 diabtes has a decresed fir...
Eligibility Criteria
Inclusion
- Type 2 diabtes according to the WHO criteria Fasting blood glucose \>7 HbA1c between 6-9 Normal liver function Normal renal function
- \-
Exclusion
- Ongoing treatment with antidiabetic medicine Pregnancy and lactation -
Key Trial Info
Start Date :
March 1 2005
Trial Type :
INTERVENTIONAL
End Date :
March 1 2006
Estimated Enrollment :
20 Patients enrolled
Trial Details
Trial ID
NCT00254085
Start Date
March 1 2005
End Date
March 1 2006
Last Update
November 15 2005
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Gentofte University Hospital
Hellerup, Hellerup, Denmark, 2900